Pure Bioscience (PURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 07/31
(Values in U.S. thousands)
| 07-2025 | 07-2024 | 07-2023 | 07-2022 | 07-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,399 | -3,350 | -3,961 | -3,491 | -2,319 |
| Depreciation Amortization | 2 | 148 | 117 | 213 | 172 |
| Accounts receivable | -176 | -13 | -78 | 167 | 721 |
| Other Working Capital | 235 | 397 | -107 | 103 | -11 |
| Other Operating Activity | 323 | 287 | 751 | 590 | 270 |
| Operating Cash Flow | $-2,015 | $-2,531 | $-3,278 | $-2,418 | $-1,167 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | -33 | -81 | -521 |
| Investing Cash Flow | $N/A | $N/A | $-33 | $-81 | $-521 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 2,000 | 1,785 | 1,015 | N/A | 239 |
| Common Stock Issued | N/A | N/A | N/A | 3,500 | N/A |
| Financing Cash Flow | $2,000 | $1,785 | $1,015 | $3,500 | $239 |
| Beginning Cash Position | 424 | 1,170 | 3,466 | 2,465 | 3,914 |
| End Cash Position | 409 | 424 | 1,170 | 3,466 | 2,465 |
| Net Cash Flow | $-15 | $-746 | $-2,296 | $1,001 | $-1,449 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,015 | -2,531 | -3,278 | -2,418 | -1,167 |
| Capital Expenditure | N/A | N/A | -33 | -81 | -521 |
| Free Cash Flow | -2,015 | -2,531 | -3,311 | -2,499 | -1,688 |